Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENvue Medical (FEED) Current Deferred Revenue (2021 - 2025)

Historic Current Deferred Revenue for ENvue Medical (FEED) over the last 5 years, with Q1 2025 value amounting to $4000.0.

  • ENvue Medical's Current Deferred Revenue fell 9130.43% to $4000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $4000.0, marking a year-over-year decrease of 9130.43%. This contributed to the annual value of $15000.0 for FY2024, which is 6739.13% down from last year.
  • Latest data reveals that ENvue Medical reported Current Deferred Revenue of $4000.0 as of Q1 2025, which was down 9130.43% from $15000.0 recorded in Q4 2024.
  • In the past 5 years, ENvue Medical's Current Deferred Revenue registered a high of $116000.0 during Q1 2021, and its lowest value of $4000.0 during Q1 2025.
  • Its 5-year average for Current Deferred Revenue is $41416.7, with a median of $44000.0 in 2021.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first skyrocketed by 11904.76% in 2023, then crashed by 9130.43% in 2025.
  • Quarter analysis of 5 years shows ENvue Medical's Current Deferred Revenue stood at $44000.0 in 2021, then plummeted by 52.27% to $21000.0 in 2022, then surged by 119.05% to $46000.0 in 2023, then plummeted by 67.39% to $15000.0 in 2024, then crashed by 73.33% to $4000.0 in 2025.
  • Its Current Deferred Revenue was $4000.0 in Q1 2025, compared to $15000.0 in Q4 2024 and $27000.0 in Q3 2024.